The Shanghai Municipal Food and Drug Safety Commission issued a 15th Five-Year Plan to ensure drug safety and promote high-quality pharmaceutical development, outlining multiple regulatory reforms. It will deepen clinical-trial review and approval reforms for innovative drugs and support R&D. The plan calls for reforming review and approval procedures for supplemental applications for domestic and overseas chemical drug production and offering front-end support for major change filings on local

Shanghai municipal Food and Drug Safety Committee issued its 15th Five-Year plan to ensure drug safety and promote high-quality pharmaceutical development, calling for targeted supervision of priority fields and products. It mandates establishment of accountability and risk‑sharing mechanisms for contract manufacturing and enforcement of quality‑and‑safety responsibilities defined in contract manufacturing agreements. The plan orders intensified on-site inspections at vaccine producers and full-coverage targeted supervision for vaccines, blood products, advanced therapy drugs, sterile pharmaceuticals, special-category medicines and products with segmented production processes, with emphasis on data reliability, sterility assurance, deviation control and change management. It also tightens oversight of implantable and sterile medical devices and devices selected via centralized procurement, requires one-product/one-policy regulatory plans for innovative devices, and steps up checks on procurement of critical raw materials, finished‑product testing and release. Separately, Shanghai will launch a production quality-management upgrade for cosmetics manufacturers, prioritizing special-use cosmetics and products using new raw materials and strengthening raw‑material controls.

美國國務卿魯比奧：我們看到選舉結果有時朝着一個方向發展，幾年後又朝着另一個方向發展。